NIH starts clinical research consortium

Oct 03, 2006

The U.S. National Institutes of Health is forming a consortium to transform how the nation's clinical and translational research is conducted.

The consortium begins with 12 academic health centers located across the nation. An additional 52 centers will receive planning grants to help them prepare applications to join the group.

When fully implemented in 2012, about 60 institutions will be linked to energize the discipline of clinical and translational science.

"The development of this consortium represents the first systematic change in our approach to clinical research in 50 years," said NIH Director Elias Zerhouni. "Working together, these sites will serve as discovery engines that will improve medical care by applying new scientific advances to real world practice.

The first set of five-year grants will be awarded: Columbia University Health Sciences, Duke University, the Mayo Clinic College of Medicine, the Oregon Health & Science University, Rockefeller University, Yale University, the Texas Health Science Center, and the universities of California-Davis, California-San Francisco, Pennsylvania, Pittsburgh and Rochester.

Copyright 2006 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

Rabbits kept indoors could be vitamin D deficient

Apr 09, 2014

Rabbits that remain indoors may suffer from a lack of vitamin D, researchers report in a new study. In rabbits kept as pets or used in laboratory studies, the deficiency could lead to dental problems, undermine ...

Amino acid fingerprints revealed in new study

Apr 06, 2014

Some three billion base pairs make up the human genome—the floor plan of life. In 2003, the Human Genome Project announced the successful decryption of this code, a tour de force that continues to supply ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Ocean microbes display remarkable genetic diversity

The smallest, most abundant marine microbe, Prochlorococcus, is a photosynthetic bacteria species essential to the marine ecosystem. An estimated billion billion billion of the single-cell creatures live i ...

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.